Eurofins Scientific Acquires 30,000 Own Shares on the Market
Eurofins Scientific acquired 30,000 own shares between January 12 and January 16, 2026 on Euronext Paris, according to a statement released this Monday. The weighted average price was set at 71.91 euros per share.
According to the group, the repurchases were spread over five consecutive trading sessions. On January 12, 10,000 shares were acquired at an average price of 70.5975 euros. In the following days, 5,000 shares were repurchased daily, at average prices of 72.9633 euros on January 13, 72.6177 euros on January 14, 72.2203 euros on January 15, and 72.4636 euros on January 16. All transactions were carried out on the regulated market Euronext Paris, identified by the code XPAR. The statement specifies that these operations involve the financial instrument FR0014000MR3, corresponding to the company's ordinary shares.
Context of the Share Buyback
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
These share repurchases are part of the company's own share buyback program, the company indicates. In accordance with Article 5, paragraph 1, point b, of European Regulation number 596/2014 on market abuse, Eurofins Scientific publishes the full details of the individual transactions on its investor website. The issuer identifier code used in the declaration is 529900JEHFM47DYY3S57.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
